top of page

Combination of multivalent DC vaccine + NK cell therapy

Tokyo Cancer Clinic 

◎​multivalent DC vaccine

Everyone must be very curious about the multivalent dendritic cell vaccine. According to the information provided by the Tokyo Cancer Clinic (formerly: Abe Medical Oncology Clinic), they also provide the fifth generation of specific immune cell therapy, and also use non-specific Sexual NK cells together to increase the effect. The main mechanism of specific immunotherapy is that the dendritic cell vaccine is delivered to T cells through various characteristics on the surface of cancer cells, and then activated into killer T cells to attack cancer cells. However, cancer cells still evade this mechanism by hiding these features. Multivalent dendritic cell vaccine is the characteristic of true cancer cells. It is combined with more than four overlapping and long-chain peptides suitable for patients such as WT1, NY-ESO-1, MAGE-A3, etc. to create a multivalent tree Stem Cell Vaccine. Another characteristic is that these peptides have MHC class I and class II.

What is the difference between long-chain peptides? Long chains can prevent the competition between antigens. The 2010 Forum on Vaccine Science pointed out that the length of the peptide is quite important. If it is a short chain, it will be difficult to combine with the MHC class I of dendritic cells, resulting in the inability to fully activate the antigen prompts to T cells, and cannot fully attack cancer cells.

In addition to using a long-chain peptide with 13 amino acids, it also has the characteristics of overlapping. Therefore, according to Dr. Abe's theory, these peptides do not need to be matched with HLA (white blood cell type), and can also be applied to various cancer patients. At the same time, they can also activate helper T cells. The difference between chain peptides and short chains.

In order to distinguish it from other immunotherapies, Dr. Abe specially applied for patents in Japan and the United States, and named it ABeVax® (Anticancer Binary Epitope Vaccine), and will continue to challenge this field in the future.

◎Treatment Features

◎Introduction to doctors and clinics


1964  Graduated from Sapporo Medical University.

Keio University Affiliated Hospital to study in the United States after internship

After that, he will be a lecturer at Shuntian University

Assistant Professor at Nihon University

Visiting professors at Stanford University, University of California, and Kyorin University

1988   established medical corporation Boshin Welfare Association

Honorary Dean of Jiuduan Clinic

ABE Medical Oncology Clinic

Director of Kudan Clinic Mito

In May 2002, he was awarded the "Major Contribution Award for Cancer Treatment and Prevention" by the World Life Research Institute, USA

Cancer Control Society presented "Cancer and Immunotherapy Pharmacognostic Research Achievements"

In April 2013, he won the International Cell and Molecular Correction Medicine Popularization Contribution Award

Dr. Abe also has numerous publications and media interviews. In addition, the hospital also has several patents for immune cell therapy in Japan, Taiwan, South Korea, and the United States. When we assist patients in their treatment, some use apheresis to take out the white blood cells in the blood. It takes about 2 to 3 hours each time, and about 5,000ml of blood in the body will be sent to the outside of the body by dialysis to obtain the mononucleus. On their side, without avoiding the burden on patients, they adopt the model of drawing blood every time, with the exclusive patents of Japan and the United States, and a small amount of blood can make dendritic cell vaccines. Generally, when they are used, they will be promoted together with NK cells. So how much blood will be collected in this way? 25ml is enough! Probably the least amount of blood we have ever collected since we joined the army. Generally speaking, since mononuclear cells account for 3-9% of the blood, if no components are used, 60-80ml of the patient needs to be drawn each time to obtain enough mononuclear cells. The nuclear sphere is really different before the exclusive patent. On the one hand, it can reduce the burden on the patient's body, and on the other hand, it can reduce the chance of infection for patients who are in the component blood collection for a long time. According to the hospital's information, each dendritic cell vaccine has at least 1×10^7, and the live cell rate is over 97%.

◎Technical patent


◎Treatment costs

The immune cell therapy provided by the hospital and its charging standard (Japanese yen denominated, tax excluded)

1. Multivalent dendritic cell therapy + active NK cell therapy  3,100,000 (one course of five treatments)

2. Multivalent dendritic cell therapy + active NK/NKT/ɤδT cell therapy 3,250,000 (one course of five treatments)

3. Multivalent dendritic cell therapy  2,520,000 (one course of six treatments)

4. Active NK cell therapy 1,620,000 (one course of six treatments)

5. Active NK/NKT/ɤδT cell therapy 1,800,000 (one course of six treatments)

​*The above prices are for reference only, the details are subject to the hospital

 〒102-0072 Chiyoda-ku, Tokyo

9th Floor, Akebono Building Building, No. 1-3-2, Iidabashi

◎Clinic address



If you have any questions, please feel free to contact us through any of the methods below.

Name: *

Mailbox: *

Telephone: *




TW contact only: +886-90-5563-717

JP For emergency contact: +81-80-4276-3930


​JP Tel / Fax:  +81-92 -984-3200



LINE@ ID: @medicalsupporter


LINE & WeChat & Skype: medicalsupporter

  • Facebook
  • Instagram
bottom of page